Targeting tropomyosin receptor kinase for cancer therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting tropomyosin receptor kinase for cancer therapy

Published:2019-08 Issue: Volume:175 Page:129-148
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Miao Qi^ORCID,Ma Kun,Chen Dong,Wu Xiaoxing,Jiang Sheng^ORCID

Funder

National Natural Science Foundation of China

Double First-Class University Project

National Major Scientific and Technological Program for Drug Discovery

International Cooperation

State Key Laboratory of Natural Medicines

China Pharmaceutical University

Chinese Pharmaceutical Association-Yiling Biopharmaceutical Innovation Foundation

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference115 articles.

1. World Cancer Report 2014;Stewart,2014

2. Precision medicine for cancer with next-generation functional diagnostics;Friedman;Nat. Rev. Canc.,2015

3. Precision public health for the era of precision medicine;Khoury;Am. J. Prev. Med.,2016

4. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences;Martin-Zanca;Nature,1986

5. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition;Bertrand;J. Mol. Biol.,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular pathway of pancreatic cancer‐associated neuropathic pain;Journal of Biochemical and Molecular Toxicology;2024-04

2. Design, synthesis, and biological evaluation of novel discoidin domain receptor inhibitors for the treatment of lung adenocarcinoma and pulmonary fibrosis;European Journal of Medicinal Chemistry;2024-02

3. Nerve Growth Factor and the Role of Inflammation in Tumor Development;Current Issues in Molecular Biology;2024-01-23

4. Exploring the untapped pharmacological potential of imidazopyridazines;RSC Advances;2024

5. Design of potential anti-cancer agents as COX-2 inhibitors, using 3D-QSAR modeling, molecular docking, oral bioavailability proprieties, and molecular dynamics simulation;Anti-Cancer Drugs;2023-11-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3